Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Nuertingen – page 75

961 clinical trials in Nuertingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nuertingen at a glance
961
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

961 trials in Nuertingen

Open in trial search

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Venetoclax and Azacitidine for Adults 18+ with Acute Myeloid Leukemia Not Eligible for Standard Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:University of Leipzig

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pehero
  • Sponsor:Arctic Bioscience AS

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Back pain

Not recruiting

Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aceclofenac
  • Sponsor:Apurano Pharmaceuticals GmbH

Pain+1

Not recruiting

Study on the Effectiveness and Safety of AP707 with Lamotrigine and Amitriptyline for Patients with Chronic Central Neuropathic Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Pain+1

Not recruiting

Study on the Effectiveness of AP707, Gabapentin, and Capsaicin for Patients with Chronic Pain from Traumatic or Post-Operative Peripheral Neuropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Retinitis pigmentosa

Not recruiting

Study on the Effects of Oral N-Acetylcysteine for Patients with Retinitis Pigmentosa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Acetylcysteine
  • Sponsor:Johns Hopkins University

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Partial seizures

Not recruiting

Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Nuertingen

What the registry says about research in the country

01 Neoplasms

Clinical trial research in Nürtingen is focused on neoplasms, with studies centered on improving treatment options and patient outcomes in cancer care.

  • Focus on prostate cancer and renal cell carcinoma
  • Evaluating new approaches for metastatic castration-sensitive prostate cancer
  • Testing combination treatments for previously untreated locally advanced unresectable or metastatic renal cell carcinoma
  • Assessing both treatment effectiveness and tolerability

These studies aim to refine cancer therapy, with an emphasis on balancing disease control, safety, and patient comfort.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.